![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Imbruvica First Indication in Chronic Graft-Versus-Host Disease
FDA Grants Imbruvica First Indication in Chronic Graft-Versus-Host Disease
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
The FDA expanded its approval of Pharmacyclics’ Imbruvica (ibrutinib) to include the treatment chronic graft versus host disease after failure of one or more treatments — making it the first FDA-approved therapy for the treatment of cGVHD, which is estimated to occur in 30-70 percent of all patients that receive hematopoietic stem cell transplants.
Richard Pazdur, director of the FDA’s Oncology Center of Excellence, said the approval highlights how a known cancer treatment can find new use in treating a condition that may occur in patients with blood cancer. The FDA granted the application priority review, orphan drug and breakthrough therapy designations.
Imbruvica was studied in a single-arm trial of 42 patients with cGVHD whose symptoms persisted despite standard treatment with corticosteroids, with two-thirds of patients showing improvements in symptoms. In 48 percent of patients, improvements lasted five months or longer.
Upcoming Events
-
21Oct